Pfizer’s (PFE) inflammation and immunology (or I&I) drug Xeljanz has seen strong growth trends in 2016. The growth is mainly due to Xeljanz’s high efficacy as a monotherapy and increasing brand awareness. Xeljanz is also included in the guidelines for the treatment of rheumatoid arthritis (or RA) by the American College of Rheumatology.
The launch of Xeljanz XR (extended release Xeljanz) helped boost the drug’s sales in 2016. To know more about these trends, please refer to Xeljanz ER Is Driving Growth for Pfizer This Year.
Wall Street analysts have projected that Xeljanz’s revenues will rise year-over-year about 67.5%, from $523.0 million in 2015 to $876.0 million in 2016.
If Xeljanz manages to surpass this revenue target, it may boost Pfizer’s share price as well as shares of the iShares Core High Dividend (HDV). Pfizer makes up about 5.0% of HDV’s total portfolio holdings.
On March 23, 2016, the EMA (European Medicines Agency) accepted for review Xeljanz’s application for regulatory approval as a therapy for RA patients who don’t respond sufficiently or are unable to tolerate methotrexate. This application includes additional data based on the oral development program. The data further establish the efficacy and safety of Xeljanz. Pfizer expects a positive response from the EMA.
In 2017, Pfizer plans to file an application with the FDA (U.S. Food and Drug Administration) to seek approval for Xeljanz as a therapy for ulcerative colitis and psoriatic arthritis. These developments are expected to enable Pfizer to pose strong competition to other I&I players such as AbbVie (ABBV), Celgene (CELG), and Johnson & Johnson (JNJ).
In the next part of this series, we’ll explore the growth prospects of crisaborole, an investigational drug.